

# INPLASY PROTOCOL

To cite: Li et al. Prognostic and Clinicopathologic Significance of Neutrophil-to-lymphocyte Ratio in Esophageal Cancer: An Update Meta-analysis. Inplasy protocol 2021100111. doi: 10.37766/inplasy2021.10.0111

Received: 28 October 2021

Published: 28 October 2021

**Corresponding author:**  
Sheng Wang

swangcancr@163.com

**Support:** Private ownership.

**Review Stage at time of this submission:** Data analysis - Completed but not published.

**Conflicts of interest:**  
None declared.

## Prognostic and Clinicopathologic Significance of Neutrophil-to-lymphocyte Ratio in Esophageal Cancer: An Update Meta-analysis

Li, B<sup>1</sup>; Xiong, F<sup>2</sup>; Yi, S<sup>3</sup>; Wang, S<sup>4</sup>.

**Review question / Objective:** Assess the prognostic and clinicopathologic significance of Neutrophil-to-lymphocyte Ratio (NLR) in patients with esophageal cancer.

**Condition being studied:** Prognosis and clinicopathologic characteristics of esophageal cancer.

**Eligibility criteria:** 1) esophageal cancer was diagnosed with pathology; 2) NLR was measured before treatment and from serum and with a clear cutoff value; 3) the association between NLR and prognosis (OS, CSS, PFS, and DFS) or clinicopathologic parameters were evaluated.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 28 October 2021 and was last updated on 28 October 2021 (registration number INPLASY2021100111).

### INTRODUCTION

**Review question / Objective:** Assess the prognostic and clinicopathologic significance of Neutrophil-to-lymphocyte Ratio (NLR) in patients with esophageal cancer.

**Condition being studied:** Prognosis and clinicopathologic characteristics of esophageal cancer.

### METHODS

**Participant or population:** Patients who were diagnosed with esophageal cancer.

**Intervention:** None.

**Comparator:** None.

**Study designs to be included:** a Meta-Analysis.

---

**Eligibility criteria:** 1) esophageal cancer was diagnosed with pathology; 2) NLR was measured before treatment and from serum and with a clear cutoff value; 3) the association between NLR and prognosis (OS, CSS, PFS, and DFS) or clinicopathologic parameters were evaluated.

**Information sources:** A systematic literature search was performed using PubMed, Embase, and Web of Science up to January 12, 2020.

**Main outcome(s):** Overall survival of esophageal cancer.

**Quality assessment / Risk of bias analysis:** Publication bias was assessed using Begg's funnel plot and Egger's linear regression test.

**Strategy of data synthesis:** HRs and 95% CIs were used to analyze the relationship between NLR and prognosis (OS, CSS, PFS, and DFS); if univariate and multivariate analyses were both reported in the same study, multivariate-adjusted HRs and 95% confidence intervals were used in preference. ORs and 95% CIs were used to evaluate the relationship between NLR and clinicopathologic factors.

**Subgroup analysis:** Subgroup analysis was used to explore possible heterogeneity.

**Sensitivity analysis:** Robustness of the study was tested by sensitivity analysis

**Country(ies) involved:** China.

**Keywords:** esophageal cancer; inflammation; meta-analysis; neutrophil-to-lymphocyteratio.

**Contributions of each author:**

Author 1 - Binfeng Li - conceived the study, and performed the literature search and collected the data.

Email: [bflicancer@163.com](mailto:bflicancer@163.com)

Author 2 - Fei Xiong - performed the literature search and collected the data, and assessed the study quality.

Author 3 - Shengzhong Yi - revised the manuscript and language, and assessed the study quality.

Email: [2351627732@qq.com](mailto:2351627732@qq.com)

Author 4 - Sheng Wang - conceived the study, assessed the study quality and revised the manuscript and language.

Email: [swangcancer@163.com](mailto:swangcancer@163.com)